Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors

Journal of Experimental Medicine

Volumn 203, Issue 3, 2006, Pages 789-797

  Kaneko, Yoshikatsu ^a   Nimmerjahn, Falk ^a   Madaio, Michael P ^b   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; FC RECEPTOR ANTIBODY; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ALLOGENEIC RESTRICTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; EFFECTOR CELL; EXPERIMENTAL MODEL; FEMALE; GLOMERULUS; IMMUNE COMPLEX NEPHRITIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RENAL PROTECTION; SENSITIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; DOWN-REGULATION; GLOMERULAR BASEMENT MEMBRANE; HUMANS; IMMUNE COMPLEX DISEASES; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MACROPHAGES; MICE; NEPHRITIS; RECEPTORS, FC; UP-REGULATION;

EID: 33645080442     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20051900     Document Type: Article

References (44)

1. Ravetch, J.V., and R.A. Clynes. 1998. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16:421-432.
2. Takai, T., M. Li, D. Sylvestre, R. Clynes, and J.V. Ravetch. 1994. FcR γ chain deletion results in pleiotrophic effector cell defects. Cell. 76:519-529.
3. Sylvestre, D.L., and J.V. Ravetch. 1994. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science. 265:1095-1098.
4. Sylvestre, D.L., and J.V. Ravetch. 1996. A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity. 5:387-390.
5. Clynes, R., and J.V. Ravetch. 1995. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 3:21-26.
6. Clynes, R., C. Dumitru, and J.V. Ravetch. 1998. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science. 279:1052-1054.
7. Ravetch, J.V., and L.L. Lanier. 2000. Immune inhibitory receptors. Science. 290:84-89.
8. Takai, T., M. Ono, M. Hikida, H. Ohmori, and J.V. Ravetch. 1996. Augmented humoral and anaphylactic responses in FcaγRII-deficient mice. Nature. 379:346-349.
9. Clynes, R.A., T.L. Towers, L.G. Presta, and J.V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443-446.
10. b mice susceptible to collagen-induced arthritis. J. Exp. Med. 189:187-194.
11. Nakamura, A., T. Yuasa, A. Ujike, M. Ono, T. Nukiwa, J.V. Ravetch, and T. Takai. 2000. Fcaγ receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J. Exp. Med. 191:899-905.
12. Ravetch, J.V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19:275-290.
13. Nimmerjahn, F., P. Bruhns, K. Horiuchi, and J.V. Ravetch. 2005. FcaγRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 23:41-51.
14. Nimmerjahn, F., and J.V. Ravetch. 2005. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science. 310:1510-1512.
15. Guyre, P.M., P.M. Morganelli, and R. Miller. 1983. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J. Clin. Invest. 72:393-397.
16. Shushakova, N., J. Skokowa, J. Schulman, U. Baumann, J. Zwirner, R.E. Schmidt, and J.E. Gessner. 2002. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcaγRs in immune complex-induced lung disease. J. Clin. Invest. 110:1823-1830.
17. Ravetch, J.V. 2002. A full complement of receptors in immune complex disease. J. Clin. Invest. 110:1759-1761.
18. Samuelsson, A., T.L. Towers, and J.V. Ravetch. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 291:484-486.
19. Bruhns, P., A. Samuelsson, J.W. Pollard, and J.V. Ravetch. 2003. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 18:573-581.
20. Lerner, R.A., R.J. Glassock, and F.J. Dixon. 1967. The role of antiglomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J. Exp. Med. 126:989-1004.
21. Kerr, P.G., S.J. Chadban, and R.C. Atkins. 2001. Rapidly progressive glomerulonephritis. In Diseases of the Kidney and Urinary Tract, seventh edition. R.W. Schrier, editor. Lippincott Williams & Wilkins, Philadelphia, PA. 1665-1690.
22. Falk, R.J., J.C. Jennette, and P.H. Nachman. 2004. Primary glomerular disease. In Brenner & Rector's The Kidney, seventh edition. B.M. Brenner, editor. Saunders, Philadelphia, PA. 1293-1380.
23. Groggel, G.C., D.J. Salant, C. Darby, H.G. Rennke, and W.G. Couser. 1985. Role of terminal complement pathway in the heterologous phase of antiglomerular basement membrane nephritis. Kidney Int. 27:643-651.
24. Schrijver, G., M.J. Bogman, K.J. Assmann, R.M. de Waal, H.C. Robben, H. van Gasteren, and R.A. Koene. 1990. Anti-GBM nephritis in the mouse: role of granulocytes in the heterologous phase. Kidney Int. 38:86-95.
25. Park, S.Y., S. Ueda, H. Ohno, Y. Hamano, M. Tanaka, T. Shiratori, T. Yamazaki, H. Arase, N. Arase, A. Karasawa, et al. 1998. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J. Clin. Invest. 102:1229-1238.
26. Suzuki, Y., I. Shirato, K. Okumura, J.V. Ravetch, T. Takai, Y. Tomino, and C. Ra. 1998. Distinct contribution of Fc receptors and antiogensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int. 54:1166-1174.
27. Meyer, D., C. Schiller, J. Westermann, S. Izui, W.L.W. Hazenbos, J.S. Verbeek, R.E. Schmidt, and J.E. Gessner. 1998. FcγRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood. 92:3997-4002.
28. Fossati-Jimack, L., A. Ioan-Facsinay, L. Reininger, Y. Chicheportiche, N. Watanabe, T. Saito, F.M.A. Hofhuis, J.E. Gessner, C. Schiller, R.E. Schmidt, et al. 2000. Markedly different pathogenicity of four immunoglobulin G isotype-switch variations of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III. J. Exp. Med. 191:1293-1302.
29. Uchida, J., Y. Hamaguchi, J.A. Oliver, J.V. Ravetch, J.C. Poe, K.M. Haas, and T.F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199:1659-1669.
30. Hazenbos, W.L.W., J.E. Gessner, F.M.A. Hofhuis, H. Kuipers, D. Meyer, I.A.F.M. Heijnen, R.E. Schmidt, M. Sandor, P.J.A. Capel, M. Daeron, et al. 1996. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice. Immunity. 5:181-188.
31. Ravetch, J.V., and J.P. Kinet. 1991. Fc receptors. Annu. Rev. Immunol. 9:457-492.
32. Barnes, N., A.L. Gavin, P.S. Tan, P. Mottram, F. Koentgen, and P.M. Hogarth. 2002. FcγRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity. 16:379-389.
33. Coutelier, J.P., J.T. van der Logt, F.W. Heessen, G. Warnier, and J. van Snick. 1987. IgG2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 165:64-69.
34. Baldridge, J.R., and M.J. Buchmeier. 1992. Mechanism of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J. Virol. 66:4252-4257.
35. Markine-Goriaynoff, D., and J.P. Coutelier. 2002. Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioenchephalomyelitis revealed with switch mutants. J. Virol. 76:432-435.
36. Coimbra, T., R. Wiggins, J.W. Noh, S. Merritt, and S.H. Phan. 1991. Transforming growth factor-β production in anti-glomerular basement membrane disease in the rabbit. Am. J. Pathol. 138:223-234.
37. Border, W.A., and N.A. Noble. 1994. Transforming growth factor β in tissue fibrosis. N. Engl. J. Med. 331:1286-1292.
38. Kitamura, M., and T.S. Sütö. 1997. TGF-β and glomerulonephritis: anti-inflammatory versus prosclerotic actions. Nephrol. Dial. Transplant. 12:669-679.
39. Coffman, R.L., D.A. Lebman, and B. Shrader. 1989. Transforming growth factor β specifically enhances IgA production by lipopolysaccharide- stimulated murine B lymphocytes. J. Exp. Med. 170:1039-1044.
40. McIntyre, T.M., D.R. Klinman, P. Rothman, M. Lugo, J.R. Dasch, J.J. Mond, and C.M. Snapper. 1993. Transforming growth factor β1 selectively stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. J. Exp. Med. 177:1031-1037.
41. Fujii, T., Y. Hamano, S. Ueda, B. Akikusa, S. Yamasaki, M. Ogawa, H. Saisho, J.S. Verbeek, S. Taki, and T. Saito. 2003. Predominant role of FcaγRIII in the induction of accelerated nephrotoxic glomerulonephritis. Kidney Int. 64:1406-1416.
42. Tarzi, R.M., K.A. Davies, J.W.C. Claassens, J.S. Verbeek, M.J. Walport, and H.T. Cook. 2003. Both Fcaγ receptor I and Fcaγ receptor III mediate disease in accelerated nephrotoxic nephritis. Am. J. Pathol. 162:1677-1683.
43. Madaio, M.P., D.J. Salant, S. Adler, C. Darby, and W.G. Couser. 1984. Effect of antibody charge and concentration on deposition of antibody to glomerular basement membrane. Kidney Int. 26:397-403.
44. Chan, O., M.P. Madaio, and M.J. Shlomchik. 1997. The role of B cells in MRL/lpr murine lupus. Ann. N.Y. Acad. Sci. 815:75-87.